Adjuvant chemotherapy trial for early-stage lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a chemotherapy drug called SMS001 (a form of paclitaxel) after surgery for non-small cell lung cancer. It may help prevent the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have non-small cell lung cancer (a common type of lung cancer).
- Your cancer must be at stage 1b, 2a, 2b, or 3a (N2), and you must be scheduled for surgery to remove it completely.
- You must be 18 years or older and healthy enough for lung cancer surgery.
- You must not have had chemotherapy or radiation to the chest before.
- Your liver and kidney function must be within normal limits, and your blood counts must be adequate.
- You must agree to use effective birth control if you or your partner could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of medicines given before surgery and immunotherapy after surgery for resectable non-small cell lung cancer (NSCLC). It aims to shrink the tumor before the operation and reduce the risk of cancer coming back after surgery.
This trial tests a new approach for people with certain advanced non-small cell lung cancer (NSCLC) that has spread to lymph nodes in the chest but might still be removed. It combines a short course of high-precision radiation, immunotherapy (sintilimab), and standard chemotherapy before surgery to see if it can improve outcomes.
This trial tests a combination of radiation therapy before surgery, followed by the immunotherapy drug tislelizumab and the targeted therapy drug anlotinib after surgery, for people with stage II to IIIA non-small cell lung cancer (NSCLC). The goal is to see if this approach can improve outcomes for patients whose tumors can be removed surgically.
This trial tests a pill form of chemotherapy (oral paclitaxel) combined with an immunotherapy drug to keep advanced lung cancer from growing after initial treatment. It may help patients whose cancer was controlled with first-line therapy.
This trial studies adding an immunotherapy drug (sintilimab) to standard chemotherapy before surgery for resectable squamous non-small cell lung cancer. It aims to shrink the tumor and improve outcomes, while still keeping the cancer operable.
This trial tests whether giving chemotherapy plus immunotherapy before surgery helps people with a specific type of advanced lung cancer. It aims to see if this approach can shrink tumors and make surgery more effective.
Hear when a new Carcinoma, Non-Small-Cell Lung Cancer (NSCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.